Skip to main content

Table 1 Ku80 expression of lung cancer detected by immunohistochemistry

From: Ku80 correlates with neoadjuvant chemotherapy resistance in human lung adenocarcinoma, but reduces cisplatin/pemetrexed-induced apoptosis in A549 cells

Feature patients (n = 110) Ku80 protein level p
positive (n = 76) negative (n = 34)
Age at diagnosis
  ≤ 60 66 (60%) 50 (65.8%) 16 (47.1%) 0.09
  > 60 44 (40%) 26 (34.2%) 18 (52.9%)
Gender
 Male 32 (29.1%) 24 (31.6%) 8 (23.5%) 0.50
 Female 78 (70.9%) 52 (68.4%) 26 (76.5%)
Smoking status
 Never 71 (64.5%) 50 (65.8%) 21 (61.8%) 0.68
 Former or current smokers 39 (35.4) 26 (34.2) 13 (38.2%)
Stage(T)
 T1-2 58 (52.7%) 30 (39.5%) 28 (82.4%) 0.00
 T3-4 52 (47.2%) 46 (60.5%) 6 (17.6%)
Lymph node metastasis
 N0-1 47 (42.7%) 22 (28.9%) 25 (73.5%) 0.00
 N2 63 (57.2%) 54 (71.1%) 9 (26.5%)
Response to chemotherapy
 (+) 38 (34.5%) 7 (9.2%) 31 (91.2%) 0.00
 (-) 72 (65.5%) 69 (90.8%) 3 (8.8%)